The regulation of organ size is essential to human health and has fascinated biologists for centuries. Key to the growth process is the ability of most organs to integrate organ-extrinsic cues (eg, nutritional status, inflammatory processes) with organ-intrinsic information (eg, genetic programs, local signals) into a growth response that adapts to changing environmental conditions and ensures that the size of an organ is coordinated with the rest of the body. Paired organs such as the vertebrate limbs and the long bones within them are excellent models for studying this type of regulation because it is possible to manipulate one member of the pair and leave the other as an internal control. During development, growth plates at the end of each long bone produce a transient cartilage model that is progressively replaced by bone. Here, we review how proliferation and differentiation of cells within each growth plate are tightly controlled mainly by growth plate-intrinsic mechanisms that are additionally modulated by extrinsic signals. We also discuss the involvement of several signaling hubs in the integration and modulation of growth-related signals and how they could confer remarkable plasticity to the growth plate. Indeed, long bones have a significant ability for "catch-up growth" to attain normal size after a transient growth delay. We propose that the characterization of catch-up growth, in light of recent advances in physiology and cell biology, will provide long sought clues into the molecular mechanisms that underlie organ growth regulation. Importantly, catch-up growth early in life is commonly associated with metabolic disorders in adulthood, and this association is not completely understood. Further elucidation of the molecules and cellular interactions that influence organ size coordination should allow development of novel therapies for human growth disorders that are noninvasive and have minimal side effects. (Endocrine Reviews 36: 646 -680, 2015)
I. Introduction
O ne of the most fascinating questions in developmental biology, a question that has important implications for human congenital diseases, tissue regeneration, and cancer, is "how is organ growth regulated?" The topic of organ growth regulation has interested biologists for centuries; nevertheless, our molecular understanding of the process is limited and cannot be readily translated into useful therapies for most human growth disorders. Recently, however, disparate fields of biology have yielded some advances that together shed new light on the problem and are ushering in new research directions for the field of growth control. A key emerging concept in the field, and a recurring theme in this review, is that the wellrecognized organ-autonomous programs of growth regulation (eg, progressive decline in proliferative potential) interact with factors extrinsic to the organ (ie, endocrine, neuroendocrine, or otherwise) to confer the remarkable robustness that characterizes organ growth. Here, we first describe general concepts in the field of growth regulation, using several organs as examples. We then move into the developing long bones as a model to study organ size control, discussing the specific signaling pathways that govern developmental bone growth, with reference to related human growth disorders. We follow with a discussion on how the integration of previous knowledge and recent findings suggests that extrinsic and intrinsic cues are implemented at the cellular level by a network of signal transduction components to give rise to a refined growth response, uniquely adapted to the needs of each organ, including the bones. Throughout the review, we highlight some of the outstanding questions in the field of growth regulation and provide suggestions on how to approach them. In this regard, one of the topics we review is a very potent regulatory mechanism known as catch-up growth (CUG), and in the final section we discuss how it can be utilized to gain insight into those long-standing questions.
II. Basic Concepts and Mechanisms Underlying Organ Growth Regulation

A. Levels of growth regulation
During development, growth must be regulated at multiple levels: 1) size of the whole body; 2) size of each organ; and 3) size of the different tissues within an organ. Although some of the growth regulatory mechanisms are common to all levels, others are specific to each level or to particular organs. Therefore, whereas the long bones are the focus of this review, in this section we use different organs to illustrate some concepts.
A special case among the organs used to study growth regulation in vertebrates is the paired organs (eg, limbs, eyes, adrenal glands, kidneys, palatal shelves). Paired organs provide the unique experimental opportunity for growth to be altered in only one organ, leaving the other as an internal control for studying regulatory mechanisms triggered by the perturbation. Importantly, by comparing the paired organs in control animals with the control organ in experimental animals, it is possible to determine whether the latter undergoes compensatory regulation or if a local perturbation induces a systemic regulatory mechanism.
Among the paired organs, the limbs are a useful model because they can be manipulated at depth without compromising the animal's viability. Also, many conclusions obtained from limb growth regulation studies can be extrapolated to other organs. In Sections III and IV, we review the regulation of size in the vertebrate limbs. Unless otherwise indicated, all the cited data derive from mouse and, to a lesser extent, rat studies.
B. Concepts of organ size control
Canalization, developmental stability, and compensatory growth
Whereas homeostasis describes the process that preserves a stationary state, Waddington introduced the term "homeorhesis" (1) to describe the phenomenon by which an organism or organ returns to the normal sequence of developmental events, or growth trajectory, after it sustains an insult. Homeorhesis is classically divided into two components (2): 1) canalization, the processes that counteract genetic and environmental variation; and 2) developmental stability, the processes that buffer against developmental noise (stochastic perturbations during development). In this review, we focus on canalization.
A striking example of canalization is a phenomenon called catch-up growth (CUG) (see Section IV), defined as a transient increase in growth velocity after a temporary growth-delaying condition that lasts until a roughly normal growth trajectory is resumed (reviewed in Refs. [3] [4] [5] . CUG is distinct from the homeostatic mechanism known as "compensatory growth." As discussed by Williams (6) , compensatory growth involves extra growth of an organ following loss of actual tissue mass (eg, liver regeneration after partial hepatectomy), whereas CUG compensates for the loss of potential mass, ie, the tissue mass that would have been added to the organ had growth proceeded normally. A similar distinction can be made with adult organ regeneration.
metric, which can happen at different stages for different limb segments (11) (Figure 2 ). This switch from allometric to isometric growth has important implications for regenerative processes during development because regeneration of an organ during development requires an initial phase of allometric growth (the injured organ grows faster than the body), followed by isometric growth once the right proportions are reached. Recent studies in zebrafish have shown that inhibition of calcineurin activity or stimulation of bioelectric signaling delays the allometric-isometric switch in a growing and/or regenerating fin (12, 13) .
Autonomous and regulative growth
When considering compensation for developmental growth defects, an important distinction must be made as to whether the defect involves cell loss/addition or just reduced/increased proliferation. As we discuss in Section IV, this distinction is extremely important when studying the regulation of bone growth.
a. Response to cell loss or cell addition. If a developing organ is impervious to changes in cell number because all the information that determines its size is contained within its cells, the growth mode is called autonomous or nonregulative. For example, when a variable number of thymic primordia are grafted into a mouse body, the final size attained by each graft is independent of the number of grafts (Figure 3Aa ) (14) . In contrast, in cases where the size of an organ can be significantly regulated, the mechanism of size control is called regulative. For example, when a spleen primordium is grafted into an adult mouse, it grows significantly more if the host was previously splenectomized, and the more primordia that are grafted into the same body, the less each graft grows (Figure 3Ab ) (15) . With regard to cell ablation, if the number of pancreatic progenitor cells is experimentally reduced by 60 -70% during mouse development, the pancreas does not replenish the lost cells, and thus its final size is smaller than normal (Figure 3Bb ) (16) . These experiments indicate that autonomous organ growth is not guided by a target size. In contrast, if the number of liver progenitor cells is reduced by 60 -80%, the liver can catch-up to almost its normal size in only 4 days (16) . A priori, there are two ways this regulation could be achieved. In one scenario, the size of the progenitor pool is a fixed property of the organ, and new progenitors can be generated/recruited to maintain a constant number (Figure 3Bc ). In the alternative scenario, the progenitor pool cannot be replenished, but the number of cells produced by each progenitor is expanded ( Figure 3Bd ). Of importance, the second scenario requires that the progenitor cells can undergo a higher than normal number of cell divisions without exhausting their potential, at least within a certain limit. In summary, growth regulation implies the existence of mechanisms capable of: 1) assessing the size of an organ/ progenitor pool; and 2) triggering an increase or decrease in growth. The processes underlying assessment of organ size have been recently reviewed (17) , and thus, in Section II.C, we review what is known about the control of organ growth.
b. Response to impaired proliferation.
Adjustment of organ size after a transient decrease in cell proliferation can potentially utilize at least two distinct strategies. One possibility is to use the same active mechanisms utilized by regulative organs in response to cell ablation, such that growth rate is adapted to organ size (see Section II.C). The alternative possibility is that organ size is not assessed and instead the growth rate of the organ is inversely dependent on the amount of growth achieved (eg, number of cell divisions), such that the organ behaves autonomously and stops growing when a particular number of cell divisions is reached. In this case, the organ cannot cope with cell addition/ablation because the total number of cell divisions remains unaltered by the perturbation. We elaborate more on this strategy in Section II.C.
C. Intrinsic and extrinsic mechanisms of growth control in vertebrates
1. General strategies to control organ growth Table 1 summarizes three basic strategies that could be employed to control organ growth and size: 1) negative feedback between organ mass and growth; 2) balanced replacement of damaged/unfit cells; and 3) growth cessation after a defined amount of growth. The first two strategies are able to compensate for cell addition/loss, whereas the last one can only cope with impaired proliferation.
a. Negative feedback between organ mass and growth. A century ago, a negative feedback mechanism was postulated to explain why some organs resume/accelerate growth after cell loss but do not overgrow once they recover a normal size (18) . The basic concept inherent to this mechanism is that the affected organ produces growth inhibitors in an amount proportional to its mass. Such putative press.endocrine.org/journal/edrvgrowth inhibitors were named chalones (from the Greek khala n, "to slack off the main sheet of a sloop to slow the vessel down") (19, 20) , and their activity was postulated to be organ-specific, nontoxic, and reversible. Although in the 1960s many tissues were clearly shown to exhibit chalone activity, the concept faded after several decades of failed purification and was only revived by the molecular studies of the late 1990s. Apart from some N-substituted oligopeptides with chalone activity (21) , most of the newly discovered chalones belong to the TGF␤ superfamily, such as myostatin in the muscle (22) , growth differentiation factor 11 in the nervous system (23, 24) , and perhaps bone morphogenetic protein (BMP) 2/4 for the hair follicle (25) and BMP3 for bone mass accrual (26) . Of note, however, these molecules do not strictly adhere to the chalone definition, for example concerning tissue specificity (27, 28) .
b. Balanced replacement of damaged/unfit cells. To replace organ mass that is either lost or not produced, one could conceive an organ-intrinsic mechanism in which a factor acting in short range is produced in proportion to the number of damaged cells. Besides diffusible or membraneanchored molecules, mechanical stretching of cells surrounding a gap in a tissue could also be considered such a factor. In turn, such factors would be able to stimulate the proliferation or hypertrophy of healthy cells, leading to a balanced replacement of the missing biomass. Importantly, compared to an adult homeostatic scenario, the situation in a developing organ is probably more complex because the organ has to keep growing and not just maintain its size. In any case, compensatory proliferation and hypertrophy have been described in response to cytokines, growth factors, or mechanical stretching generated by the damaged cells (reviewed in Refs. 29 -31) . In some organs, if the damage surpasses a certain threshold, it triggers an organ-level response, instead of just affecting cells surrounding an injury (32) . An additional fascinating cell nonautonomous mechanism known as cell competition operates within some organs, whereby metabolically healthy cells actively eliminate and replace "unfit" but otherwise viable cells while keeping the right organ mass (33) (34) (35) .
c. Growth cessation after a preprogrammed amount of growth.
As described above, one strategy to control organ size is for each cell of an organ to follow an autonomous program involving an inverse correlation between the extent of growth and the growth rate. In such a case, the extent of growth would not be measured by the concentration of a chalone, but rather by a parameter that each individual cell could quantify, such as epigenetic changes driven by each round of cell division, accumulation of a metabolic product, or any other proxy of chronological time. Indeed, there is evidence suggesting the existence of a genetic program that limits postnatal mammalian growth through involvement of a network of imprinted genes, whose expression changes as the animals grow (36 -38) . Importantly, manipulation of the diet to temporarily inhibit juvenile growth revealed that gene expression in this network is regulated by growth, not by time per se, leading to the proposal that a negative feedback loop between organ size and growth rate imposes a limit on adult body size (37, 38) . It is also interesting that several organs and tissues seem to share this program (36) , which could in theory allow for the coordination of growth between different organs without interorgan communication. Such a "blind" mechanism, however, would not be able to regulate and coordinate organ growth after local insults.
Growth modulation by extrinsic inputs
The aforementioned regulatory mechanisms can be considered organ-intrinsic because the regulative signals originate in the organ itself. However, the question remains as to whether organ growth can be modulated, or even instructed, by extrinsic inputs. In the case of the vertebrate limb, one approach to address this question has been to delete or add tissue within a limb primordium at early stages of chick development (39, 40) . After decades of conflicting results, the use of quantitative measurements and molecular Another informative set of grafting experiments involves heteroplastic transplantation of the whole limb primordium between related species differing in size. When limb buds were interchanged between chick (big) and quail (small) embryos, the size of the grafted limb was slightly yet significantly influenced by the host (42) . Fine-tuning by host factors was also seen more than 80 years ago when the transplantation involved the small salamander Amblystoma punctatum and the big but developmentally delayed A. tigrinum. At advanced stages after transplantation, once the tigrinum larva had overtaken the punctatum one in size, or even postmetamorphosis, the host exerted a mild but significant influence on the graft size (43) (Figure 4) . A similar finding was made by grafting eye primordia (43) . In summary, it is clear that growth of the limbs and eyes follows an autonomous program that can, however, be fine-tuned or influenced by extrinsic factors. Other organs may very well behave the same way.
Some studies suggest that the size of organs with vital functions (heart, brain) influences the size of all the other organs, potentially representing another example of extrinsic growth regulation. For example, elimination of the gene Brg1 in the central nervous system (CNS) of the mouse led to reduced cell number in the postnatal cortex, which resulted in the reduction of not only brain size, but also overall body size (44) . Similarly, reduction of cardiac size and function during mouse development was associated with reduced body size (45, 46) . Of course, caution must be exerted when interpreting these results because the growth retardation could be due to behavioral changes leading to impaired nutrition or other unforeseen interactions. However, from an evolutionary perspective, it is plausible that the size of vital organs imposes a limit to overall body size, and the most parsimonious mechanism would be via extrinsic modulation of organ growth. Of relevance for human pathophysiology, knowing the mechanisms involved in extrinsic organ size regulation could help reverse growth defects once the function of a vital organ has been restored.
Importantly, mathematical models suggest that the control of organ size based on regulation of progenitor behaviors suffers from intrinsic fragilities, such that only a very narrow range of ratios of symmetric-to-asymmetric stem cell divisions is compatible with system stability (47) . Regarding the relevance of extrinsic growth modulation, the models predict that the incorporation of feedback mechanisms shifts the fragilities from intrinsic to extrinsic parameters, which are easier to regulate and coordinate between different organs. For example, the effect of the epidermal chalone is enhanced by epinephrine (released by the adrenal glands), acting through ␤-adrenergic receptors (ADRs) (20, 48) . Moreover, adult liver regeneration upon partial hepatectomy depends in part on stimulation by acetylcholine, released by the parasympathetic innervation (49, 50) . Similarly, the compensatory adrenal gland growth observed upon unilateral adrenalectomy is a neural reflex that requires intact sensory and autonomic innervation (51) (52) (53) and is inhibited by the peptide neuromedin U, found in extracts of brain, spinal cord, and gastrointestinal tract (54) .
Finally, it is worth noting that ADRs, acetylcholine receptors, and neuromedin-U receptors belong to the G protein-coupled receptor (GPCR) family (reviewed in Refs. 55 and 56) , and that GPCR signaling has recently been found to be a major modulator of several growth-related pathways (see Section III.C). This is very interesting in light of press.endocrine.org/journal/edrvthe observation that some oligopeptides displaying chalone activity, such as the hemoregulatory peptide, seem to exert their action by interfering with the signal transduction of some GPCRs (57). As we discuss later, this interplay between organ-intrinsic (chalones) and extrinsic (hormones, neurotransmitters) regulatory mechanisms likely underlies the robustness of organ growth.
III. Longitudinal Bone Growth
In this section, we provide a brief summary of how long bones form and grow (Section III.A) and then describe the most common extracellular signals playing a role in the regulation of bone growth (Section III.B). Finally, we elaborate on the key concept of signal integration and cross talk as a means to confer robustness to the process of bone growth (Section III.C). For this last subsection we also introduce and elaborate on the signaling pathways and interactions that we propose are most likely to form signaling hubs.
A. Development and growth of the long bones
Long bones are formed by a process known as endochondral ossification, as opposed to the intramembranous ossification typical of the flat bones. The main difference is that the former involves the formation of a cartilage intermediate that is eventually replaced by bone. The process has been comprehensively reviewed (58, 59 ), and we summarize it here. The long bone anlage is formed when a subset of mesenchymal cells derived from the lateral plate mesoderm coalesce into morphologically distinct condensations ( Figure 5A ). The inner cells of the condensation become specified as chondrocytes, whereas the cells surrounding them form the perichondrium. Chondrocytes proliferate and produce a specialized matrix of type II collagen (encoded by Col2a1), giving rise to an ever-enlarging cartilage mould. The cells in the center of the long axis eventually stop proliferating, become hypertrophic, and change their genetic program, including expression of type X collagen. Hypertrophic chondrocytes (HTCs) are master regulatory cells that orchestrate subsequent steps of the endochondral ossification process. Perichondrial cells adjacent to HTCs become osteoblasts (bone-forming cells) and form the bone collar or periosteum ( Figure 5B ). HTCs also secrete substances that direct the formation of the mineralized cartilage matrix and recruit blood vessels that invade the center of the skeletal element; finally, the terminal chondrocytes die by apoptosis ( Figure 5C ). The cartilage matrix left behind is occupied by osteoblasts from the perichondrium, which accompany blood vessels in their invasion of the skeletal element to form the primary ossification center, composed of true bone matrix called primary spongiosa. This new bone will progressively be remodeled into trabecular bone, whereas the bone collar will form cortical bone (reviewed in Ref. 58) . The cartilage continues elongating through proliferation of non-HTCs, which organize themselves into two morphologically and molecularly distinct groups (60, 61) : slowly proliferating rounded chondrocytes, near the ends; and rapidly proliferating flat chondrocytes toward the center, arrayed in columns parallel to the direction of growth. At postnatal stages, secondary ossification centers form at the ends of the bones via a similar yet distinct process of chondrocyte hypertrophy, formation of canals within the cartilage, blood vessel invasion, and osteoblast activity (62) . The formation of two ossification centers leaves the disc-shaped cartilage (the growth plate [GP] proper) in between the two bone-forming regions and surrounded by the perichondrium ( Figure 5D ). The GP conserves the layered chondrocyte organization from the secondary toward the primary ossification center: rounded chondrocytes, which no longer proliferate and are called resting chondrocytes; flat or columnar chondrocytes, which proliferate with a cell cycle length ranging from 24 to 48 hours (63, 64) ; prehypertrophic or maturing chondrocytes; hypertrophic, and finally terminal chondrocytes ( Figure 5D ). Not all HTCs fade into oblivion, however, because recent studies have shown that a significant percentage of trabecular-bone osteoblasts (up to 50% depending on the stage) derive from the HTC population, and not from the perichondrium (65) (66) (67) . On the other hand, osteoclasts (bone-degrading cells necessary for constant bone turnover) derive entirely from hematopoietic precursors, and their differentiation is controlled by osteoblasts, ensuring that bone formation and erosion are balanced. Although the regulation of bone mass, the processes of bone modeling and remodeling, could be considered a bone growth process and has been extensively studied, in part due to the prevalence of osteoporosis in our society, we focus our review on the developmental growth that determines bone length.
The final length of a bone depends primarily on the accumulated length of the transient cartilage template laid down over time, which is proportional to HTC number and size. Thus, proliferation and differentiation of chondrocytes must be tightly regulated during long bone growth. It was recently shown that the duration of chondrocyte hypertrophy (especially the last of three distinct enlargement phases) varies between different GPs (or equivalent GPs from species differing in their bone proportions), such that the duration of the last hypertrophy phase positively correlates with the final size of the bone (68).
B. Local and systemic regulation of the growth plate
Local/intrinsic GP regulation
Local regulation of the GP involves both intracellular regulators (transcription factors) and secreted signals produced by cells within the GP (resting, proliferative, prehypertrophic, and hypertrophic chondrocytes) or secreted by adjacent cells (eg, perichondrium). Both have been extensively reviewed by experts in the field (59, 69, 70) , and here we only briefly mention the extracellular signals to define the groundwork for the subsequent discussion (see a list in Figure 5D ). Given the frequent involvement of GPCRs and their role in our discussion (see below and Section III.C), we start by summarizing GPCR signaling. Briefly, GPCRs are transmembrane receptors that associate with cytoplasmic heterotrimeric G proteins (an association of the GTPase G␣ and the G␤-␥ complex, G␤␥). Upon ligand binding, the GPCR promotes the exchange of GDP for GTP in G␣, such that the trimeric complex detaches from the GPCR and the active G␣-subunit is released from the G␤␥ complex and exerts most downstream actions. G␣ proteins are divided into four main families, based on their regulation of the activity of adenylate cyclase (stimulated by class G␣ s , inhibited by class G␣ i/o ), phospholipase C (PLC) (stimulated by G␣ q/11 ) or Rho GTPases (stimulated by G␣ 12/13 ) to initiate downstream signaling.
The Indian hedgehog (IHH)-PTHrP negative feedback loop is perhaps the best-characterized local signaling pathway that regulates chondrocyte proliferation and hypertrophy (reviewed in Ref. 58) . IHH initiates derepression of the GPCR-like protein Smoothened upon IHH binding to its receptor Patched, leading to the accumulation of the activator forms of glioma-associated oncogene (GLI) transcription factors. IHH, produced by prehypertrophic and early HTCs, is thought to diffuse toward the articular end of the GP, where it activates expression of PTHrP. PTHrP diffuses toward the center of the skeletal element, where it binds its receptor (PTH/PTHrP receptor [PTHR1]), of the GPCR family. PTHR1 signaling then inhibits Ihh expression and hypertrophic differentiation of chondrocytes up to a certain distance from the PTHrP source (71) (72) (73) (74) (75) (76) (77) . In addition, IHH and PTHrP promote chondrocyte proliferation by parallel mechanisms (78, 79) . Therefore, this loop regulates the size of the proliferative zone and couples chondrocyte proliferation and differentiation during en- press.endocrine.org/journal/edrvdochondral ossification. In addition, IHH promotes osteogenesis through signaling to osteoblast precursors in the perichondrium and to osteoblasts in the primary spongiosa (80) . Given its importance, the IHH/PTHrP feedback loop is the main conduit through which other local and some external signals exert their function-for example, affecting IHH production (see below) or GLI activity (81) . Fibroblast growth factors (FGFs) signal through their receptors (FGFRs; a subtype of receptor tyrosine kinases [RTKs] ) to activate diverse intracellular signaling modules, such as the MAPK/ERK, STAT1 (signal transducer and activator of transcription 1), PI3K (phosphatidylinositol-3-kinase), and PLC␥/protein kinase C pathways, which play very important roles in organ development in general and limb patterning, mesenchymal condensation, and GP physiology in particular (reviewed in Refs. 58, 59, 82, and 83). Most relevant for this review is the paracrine inhibitory effect that select FGFs, mainly expressed by the perichondrium, have on perinatal and postnatal chondrocyte proliferation and hypertrophic differentiation (although there is some controversy regarding the role of FGF signaling in chondrocyte differentiation) (84 -97) .
Bone morphogenetic proteins (BMPs) are members of the TGF␤ superfamily and were identified by their ability to induce ectopic endochondral ossification. BMPs signal through Ser/Thr kinase receptors, leading to the phosphorylation and activation of SMAD complexes that enter the nucleus and exert their actions (for a detailed review, see Ref. 99) . TGF␤/BMP signaling cross talks with other signaling pathways, such as MAPK, PI3K/AKT, WNT, HH, NOTCH, and several cytokines (100), leading to synergies and antagonisms that shape the net biological effect. For example, BMP signaling promotes chondrocyte proliferation, in part by synergizing with IHH and antagonizing FGF signaling, and also delays hypertrophic differentiation of chondrocytes (77, 94, (101) (102) (103) .
Wingless-Int (WNT) cysteine-rich glycoproteins signal through Frizzled receptors and the coreceptors LRP5 and LRP6 (reviewed in Ref. 104) . Canonical signaling involves the stabilization of ␤-catenin and its translocation to the nucleus, where it transcriptionally activates genes needed for chondrocyte proliferation and hypertrophic differentiation, as well as for the maintenance of the slow-cycling cells in the GP and the perichondrium (104 -106) . Noncanonical pathways (reviewed in Ref. 107) , control the transition pace between chondrocyte zones (107, 108) and the establishment of the columnar architecture of the GP (109, 110) .
IGFs are induced by GH at the tissue level and mediate many GH actions. The IGF axis consists of type 1 and type 2 receptors (IGF-1R and IGF-2R), their ligands (IGF-1 and IGF-2), IGF binding proteins (IGFBPs), and IGFBP proteases (reviewed in Ref. 111) . Notably, IGF-1R is an RTK and signals through the PI3K/AKT and MAPK/ERK pathways (reviewed in Ref. 112) , whereas IGF-2R is structurally distinct and sequesters IGF-2 to quench its levels (113, 114) . In general, locally produced IGFs (in the GP or the perichondrium) seem to be more important in the GP than circulating ligands (115) (116) (117) (118) (119) (120) (121) (122) , and they promote chondrocyte proliferation and hypertrophy, such that most mutants in this axis (except for Igf2r and some IGFBPs) display reduced growth in mice (123) (124) (125) (126) (127) (128) (129) Interestingly, Igf2 and Igf2r are subject to opposite parental imprinting, such that only the paternal Igf2 allele is expressed in most tissues (133) , whereas the transcriptionally active Igf2r allele is the maternal one (134) . Imprinting defects in the Igf2 genomic region are associated with some cases of human growth disorders such as Beckwith-Wiedemann and Russell-Silver syndromes (135) . These syndromes are associated with disproportionate growth that sometimes leads to body asymmetries (136, 137) .
Retinoic acid receptors (RARs) are nuclear receptors that normally bind to retinoic acid, the active form of vitamin A, to enter the nucleus and activate transcriptional targets (138, 139) . In the GP, RARs are necessary for chondrocyte proliferation and synthesis of extracellular matrix (ECM) components (140) . Given that the nonHTCs of the GP are retinoid-free (141), it was hypothesized that the main function of RARs in proliferative chondrocytes is to act as ligand-free transcriptional repressors (140) .
C-Type natriuretic peptide (CNP) is both a neuropeptide and a local regulator expressed in many cell types, including chondrocytes (142) , and signals through natriuretic peptide receptors (NPRs) (reviewed in Ref. 143 ). Binding of CNP to NPR2 in chondrocytes counteracts the FGF signaling branch that delays the initiation of chondrocyte hypertrophy, leading to skeletal overgrowth (144, 145) . Conversely, loss of function of Npr2 in mice phenocopies the gain of function of FGFR3, leading to dwarfism (146) .
The Cyr61-CTGF-NOV (CCN) family comprises secreted, ECM-associated proteins that regulate very diverse cell functions related to development, tissue repair, and disease (reviewed in Ref. 147 ). CCN2 protein is detected in chondrocytes, and its initially widespread expression becomes progressively restricted to HTCs and preHTCs (148, 149) . CCN2 loss in the mouse leads to severe chondrodysplasia that results in perinatal lethality caused by reduced chondrocyte proliferation, survival, and ECM production (150, 151) , whereas CCN2 overexpression in the cartilage leads to bone overgrowth, in part due to increased IGF signaling (152) .
Epidermal growth factor (EGF) signaling takes place through binding of any of the six EGF-like ligands to the EGF receptor (EGFR; an RTK), which then activates two major downstream pathways, the MAPK/ERK and the PI3K/AKT (reviewed in Ref. 153 ). Chondrocytes express EGFR and EGF-like ligands such as EGF and TGF␣ (70) , which play a prominent role in the local regulation of postnatal growth, in part by increasing IGF-1R expression (154) . Pharmacological or genetic blockade of EGFR function leads to expansion of the hypertrophic zone, associated with delayed conversion of cartilage into bone (155).
Systemic/extrinsic regulation
In addition to the local regulation, the GP is able to respond to external cues such as nutrition, inflammation, and mechanical forces, which also regulate chondrocyte behavior and bone growth (156, 157) . The following paragraphs summarize the role of some of the known external cues (see also Figure 5D ). Note that local or systemic signals do not act independently, and the refined regulation of long bone growth likely depends on a complex interplay between both types ( Figure 5D ), akin to what has been suggested for regulation of organ growth in invertebrates (158) .
The GH-IGF axis is perhaps the most studied growthrelated pathway in humans because many disorders arise from the mutation of their multiple signaling components (Table 2) . Two basic periods can be distinguished in the systemic GH-IGF axis: a GH-independent one (embryonic and early postnatal) (128, 159, 160) ; and a GH-dependent one, once the hypothalamus-pituitary axis becomes activated (2 wk of age in the mouse) (161) (162) (163) . Circulating GH binds to its receptor (GHR; a cytokine receptor with tyrosine [Tyr] kinase activity) in multiple tissues, triggering the JAK2/STAT5b signaling pathway (164, 165) . Although many effects of GH may be indirect through Igf1 induction (166), growth retardation is more severe in mice lacking both Ghr and Igf1 than that observed with either single mutant (163, 167) , suggesting that GH and IGF-1 promote longitudinal growth by both common and independent functions. In addition, GH triggers the endocrine action of IGF-1 by stimulating its production in the liver (111, 115, 116) . Insulin receptor (InsR) is also expressed in chondrocytes and plays a role in early longitudinal growth (168 -170) . Humans with homozygous deletion of this gene exhibit severe growth retardation (leprechaunism) (171) , which is somewhat recapitulated in mice with a null mutation in Insr (172) .
Thyroid hormones (T 3 and its prohormone T 4 ) are produced in the thyroid gland as the last step of the hypothalamus-pituitary-thyroid axis (reviewed in Ref. 173) . Conversion from the stable form T 4 to the active form T 3 in chondrocytes requires the enzyme deiodinase 2 (174) . Most actions of T 3 are exerted through thyroid hormone receptors (from the nuclear receptor superfamily) (175, 176) , the deletion of which results in reduced longitudinal growth, impaired chondrocyte hypertrophy, disorganized GP, and delayed mineralization, resembling the effects of hypothyroidism (177) . Conversely, elevated T 3 and T 4 plasma levels result in advanced ossification and reduced longitudinal growth due to premature GP maturation. For further details, see Refs. 173 and 178). In addition, thyroid hormone may have indirect actions on the GP via interaction with other signaling pathways such as GH, IGF, FGF, WNT, or HH (179 -181) . Reciprocally, some of the local GP regulators modulate the effect of endocrine signaling in the GP (182, 183) . Interestingly, pituitary-produced TSH, responsible for T 4 release, can also signal in chondrocytes through a GPCR (184) . When the thyroid gland is hypoactive, the resulting low levels of thyroid hormone cannot exert a strong negative feedback at the pituitary level, and TSH levels are increased. In this situation, increased TSH signaling in chondrocytes delays GP senescence, explaining the CUG that takes place once hypothyroidism is corrected (see Section IV).
Vitamin D is either synthesized by the skin or incorporated in the diet, but it needs to be converted into the active form 1,25-dihydroxy-vitamin D (1,25VD) by an ␣-hydroxylase enzyme (CYP27B1) in the target tissues. 1,25VD binds to the vitamin D receptor (VDR), a nuclear receptor that upon ligand binding translocates to the nucleus and acts on the vitamin D response elements (reviewed in Ref. 185) . Although Cyp27b1 and Vdr are expressed in chondrocytes and Vdr Ϫ/Ϫ mice display some symptoms of rickets type II (a bone mineralization problem associated with hypocalcemia and hyperparathyroidism) starting at 3 weeks of age, most VDR-dependent effects of vitamin D on bone development stem from its role in the intestinal absorption of minerals (186, 187) . 1,25VD also has some direct VDR-dependent (188) and VDR-independent roles in the GP (189), but targeted deletion or overexpression of Cyp27b1 does not have permanent effects on postnatal bone development (190) , suggesting that the endocrine effects of vitamin D and related pathways are more important than the local ones at the GP level. PTH and FGF23 (one of the few endocrine-acting FGFs) also play an important role in bone development and are interrelated with vitamin D and the maintenance of normal mineral levels via the so-called bone-kidneyparathyroid axis (see for further details). FGF23 can also have direct effects on chondrocytes. Increased levels of circulating FGF23 in a mouse model of X-linked hypophosphatemic rickets lead to reduced chondrocyte proliferation and longitudinal growth by signaling through FGFR3 (especially in the presence of the soluble form of the coreceptor ␣-klotho) (196, 197) .
Sex steroids have biphasic effects on bone growth. Although sex steroids stimulate the pubertal growth spurt in primates and other mammals, in part through the GH-IGF axis (198) , a high concentration of estrogen accelerates the progressive chondrocyte senescence that eventually leads to growth cessation and that in some species leads to GP fusion or closure (199 -201) . Although androgens stimulate chondrocyte proliferation and ECM synthesis in vitro via local IGF signaling (202) , their main contribution to growth in vivo takes place through their conversion into estrogens by the enzyme aromatase, expressed in chondrocytes (203) . Estrogen and androgen receptors (from the nuclear receptor superfamily) mediate the effects of sex steroids in chondrocytes (204 -206) , although estrogens can also signal through G protein-coupled estrogen receptor (GPER/ GPR30). Interestingly, whereas Gpr30 mutant female mice show decreased longitudinal bone growth associated with decreased GP height (207, 208) , mutant males have longer bones and bodies, associated with increased chondrocyte proliferation (209) . The cause(s) of the different growth responses are not completely understood.
Glucocorticoids (GCs) are produced as the last step of the hypothalamus-pituitary-adrenal axis (reviewed in Ref. 210 ). The GC receptor (a nuclear receptor) is expressed in most cell types, including chondrocytes, and although in natural conditions GCs play a minor role in bone growth, long-term high-dose GC treatment leads to growth failure in children (211) . Ligand-bound GC receptors can have both genomic and nongenomic functions (reviewed in Ref. 210) , and in the GP they mainly inhibit chondrocyte proliferation (212, 213) and may also induce chondrocyte apoptosis (213) . Also, very relevant for the following section, GCs stimulate production of ␤-arrestin 1 and repress production of ␤-arrestin 2 (reviewed in Ref. 210 ) that participate in transduction and subsequent desensitization of GPCR signaling. By altering the ratio of ␤-arrestin 1 and ␤-arrestin 2, GCs can modulate the signaling outcomes of a given GPCR, which might in turn modulate the effects of other growth regulators (see Sec-tion III.C). In addition to their direct effects, GCs interact with local GP signals, especially of the GH-IGF axis (118, 119, 214) .
ACTH (released by the pituitary gland to stimulate GC production in the adrenal cortex) also impacts on longitudinal bone growth. ACTH signals through melanocortin receptors (MC1R to MC5R) of the GPCR family, which can promote the cAMP/protein kinase A (PKA), the protein kinase C, and the MAPK/ERK pathways (reviewed in Ref. 215) . ACTH levels are increased in patients with GC deficiency due to the lack of negative feedback at the level of the pituitary gland, and this is associated with increased longitudinal growth and bone age, probably through a direct effect on chondrocytes (216 -218) .
Nutrition has systemic effects on growth, such as the reduction of serum GH and IGF-1 levels upon fasting (219), and at the tissue level by nutrient-sensing pathways that link the nutritional status to growth-related signaling pathways (eg, mechanistic target of rapamycin [mTOR]; see Section III.C). In addition, nutritional status affects the production of several systemic and local growth regulators: leptin, FGF21, and miR-140. Leptin, an adipocytereleased hormone, is induced by feeding and promotes bone growth despite decreasing food intake (reviewed in Ref. 156) . Upon binding to leptin receptor (a cytokine receptor with Tyr kinase activity), leptin in general promotes cell proliferation and survival through the JAK/ STAT, PI3K/AKT, and MAPK/ERK pathways. Leptin-deficient mice show decreased bone length that is associated with an advanced maturation phenotype in the hypertrophic zone of the GP (220, 221) . Although leptin deficiency in humans is not associated with decreased longitudinal growth (222, 223) , there are some suggestive correlations between high leptin levels and accelerated human growth periods (224 -226) . Leptin can directly signal to GP chondrocytes (220) , and the fact that it restores bone growth in fasted rats despite failing to increase their blunted serum IGF-1 levels (227) suggests that leptin's role on skeletal growth may be independent of the systemic GH-IGF-1 axis. The effects of leptin on chondrocyte proliferation and hypertrophy are also shaped through the interaction with local regulators of the GP, such as IHH, PTHrP, IGF-1R, and WNT/␤-catenin signaling (227, 228) , and the synergy with other endocrine signals, such as thyroid hormone (229) . FGF21, induced by undernutrition, can cause impaired growth. Like FGF23, FGF21 can diffuse far away from its source to act as an endocrine factor (reviewed in Ref. 230) . Nutritionally or genetically increased FGF21 levels correlate with decreased sensitivity to GH and reduced GP height and longitudinal growth in mice and humans (231) (232) (233) (234) , whereas food-restricted Fgf21 Ϫ/Ϫ mutant mice show improved growth and recovery of GP height as compared to food-restricted wild-type (WT) animals (235) . The antagonistic effect of FGF21 on bone growth is in part due to the induction of small transmembrane proteins that inhibit the recycling of GHR and leptin receptor (236 -238) . miR-140, a cartilage-specific miRNA (239) , is down-regulated in food-restricted rats through an unknown mechanism. Interestingly, genetic deletion of miR-140 in mice leads to stunted long bone growth, as does food restriction (240) . The mutant phenotype is associated with reduced chondrocyte proliferation, accelerated hypertrophic differentiation, and premature mineralization, probably through reduced BMP signaling, and also with impaired differentiation of resting into proliferative chondrocytes (240 -242) . Inflammatory conditions have a negative effect on growth (reviewed in Ref. 157) . Although the observed growth retardation may be in part secondary to the specific symptoms of the disease (eg, nutrient malabsorption contributes to impaired growth in the case of inflammatory bowel disease), or due to the side effects of common anti-inflammatory treatments such as GCs, the increased levels of proinflammatory cytokines observed in the course of inflammatory diseases are also associated with decreased sensitivity to GH-IGF signaling (reviewed in Refs. 157 and 243). Even if an inflammatory condition is not chronic, it can have long-lasting effects on longitudinal growth (244) . In vivo, the main effect of proinflammatory cytokines in the GP is probably related to the induction of negative feedback mechanisms that under normal conditions operate to restrict the extent of STAT5b signaling downstream of GH (245) (246) (247) (248) (249) . Some evidence suggests that this negative feedback could also affect IGF-1R signaling (250, 251) . In some cases, the inflammatory disease is also associated with reduced expression of local regulators of the GP such as PTHrP (252) .
Catecholamines and other neurotransmitters have a clear role in the regulation of bone mass (253) (254) (255) , but their role in longitudinal growth has been less studied. Norepinephrine (NEp) and Epinephrine (Ep) are produced by the adrenal medulla of the adrenal gland (NEp and Ep) and by postganglionic neurons of the sympathetic peripheral nervous system (NEp) (reviewed in Ref. press.endocrine.org/journal/edrvpathways (258, 260) . The effects of catecholamines on chondrocytes in vivo are probably limited by the ability of the ligands to diffuse from the source (sympathetic nerve fibers and blood vessels present in the ossification centers and the perichondrium) to the chondrocytes in the avascular GP.
The (263) (264) (265) (266) (267) (268) (269) .
Mechanical forces derived from normal physical activity-compression, stretching, and shear stress due to fluid flow-are necessary for normal bone growth because immobilization or continuous unloading leads to a decreased rate of bone growth and final bone length in chicken (270) and rodents (271) . Outside the physiological range, however, dynamic or static compression of long bones and vertebrae leads to reduced growth, associated with fewer proliferative chondrocytes, size of HTCs, and mineralization rate (272) (273) (274) (275) . In addition, the perichondrium exerts a growth-inhibiting compressive force on the GP because circumferential incision or stripping of the perichondrium to release the compression leads to significant overgrowth in vivo (276, 277) . Conversely, mechanical stretching induces overgrowth, associated with an elevated number of proliferative chondrocytes and enlargement of HTCs (278, 279) .
Because the magnitude of the mechanical forces born by a long bone is expected to change with bone length, mechanotransduction might be a critical feedback regulatory mechanism for bone growth. Although conclusive evidence for this putative role is missing, some early studies are consistent with the hypothesis. For example, the proximal and distal GPs of each long bone grow at very different growth rates (280, 281) , but when the GPs are interchanged within a bone, their growth rate is not maintained and adapts instead to the new position (Ref. 282 ; reviewed in English in Ref. 281 ). Because each joint bears a distinct mechanical load, the result of the experiment interchanging GPs was interpreted as meaning the mechanical load of each joint exerts a key extrinsic influence on the growth rate of each GP (281) . Although other interpretations are possible, such as a different nutritional environment in each GP, this intriguing hypothesis deserves further confirmation using modern techniques.
The mechanisms to detect mechanical forces are beyond the scope of this review and have been covered elsewhere (283, 284) . Regarding the downstream signaling, the MAPK signaling branches are almost always involved in transducing mechanical force (reviewed in Ref. 284 ). In addition, WNT/␤-catenin signaling is implicated in the response to fluid-induced shear stress (reviewed in Ref. 284) . Interestingly, Ihh is a common mechanoactivated target gene both in vitro and in vivo, involving stretchactivated channels, miRNAs, and the mTOR pathway (285) (286) (287) (288) . There are, however, many uncertainties as to the molecular response of the GP to mechanical forces. Mechanical unloading in vivo activates the expression of inducible nitric oxide (NO) synthase in GP chondrocytes, and elevated NO levels are associated with increased chondrocyte apoptosis and reduced bone growth (289) . However, mice deficient in this enzyme or the neuronal version, both expressed during skeletal development (290, 291) , show reduced chondrocyte proliferation and bone growth. Additional studies are needed to test whether, for normal bone growth, the level of NO in the GP must be maintained within a very narrow range via mechanotransduction mechanisms.
C. Signal integration. Role of the mTOR and Hippo pathways and GPCR-RTK cross talk
So far, we have mostly reviewed the effects of individual signaling pathways and how one signaling pathway can affect the expression of the ligand/receptor of another signaling pathway in the GP. But in order for growth to respond properly to all external and internal changes, further refinement mechanisms are needed for growth regulatory signals to be integrated and funneled toward meeting the specific needs of each bone. In this section, we discuss the importance of the mTOR and Hippo pathways as hubs for this critical signal integration. In addition, given that many local and systemic signals act through RTKs and GPCRs (see previous section), we review the emerging role of GPCR-RTK crosstalk in the fine-tuning of growth-regulating pathways at the postreceptor level. Hippo, mTOR, GPCRs, and RTKs seem to be highly interrelated (see below and Figure 6 ), allowing for an enormous versatility of signaling outcomes. Although most of the evidence reviewed is not from studies of bone growth or chondrocyte biology, many of the key players are present in the GP, and it therefore seems likely that some, if not all, of the described interactions contribute to regulation of long bone growth.
Mammalian/mTOR pathway
mTOR is an atypical Ser/Thr kinase of the PI3K-related kinase family and can be inhibited by rapamycin, a bac-terial macrolide with antiproliferative properties (reviewed in Ref. 292 ). The mTOR signaling pathway receives and integrates multiple extracellular inputs to regulate growth and homeostasis and therefore is implicated in many cellular processes and associated diseases (reviewed in Ref. 293) . The regulation and function of the two known mTOR complexes (mTORC1 and 2) have been reviewed elsewhere (293); here, we only provide a general summary and then focus on their effects on bone growth. a. Upstream regulators. The activity of mTORC1 is regulated by a variety of upstream inputs, such as RTK signaling in response to growth factors (IGF being one of the main ones), environmental stress, energy status, oxygen levels, and amino acids (reviewed in Refs. 293 and 294) ( Figure 6 ). As discussed earlier, muscle activity and in vitro loading activate mTOR signaling in chondrocytes (288) . In addition, mTORC1 can be activated by GPCR-dependent signaling in a variety of ways, such as direct transactivation of RTK/PI3K/AKT by GPCRs (see Section III.C.3) or by the GPCR-triggered MAPK/ ERK pathway (295).
b. Downstream effectors. The main downstream targets of mTORC1 are the kinase S6K1 and the translation initiation factor 4E-BP1, through which mTORC1 exerts many of its effects, like promotion of protein and lipid synthesis. In addition, mTORC1 blocks lysosome biogenesis and autophagy and promotes glycolysis and energy consumption. Related to Section IV (especially to the proliferative potential of stem-like cells in the GP), elevated mTOR signaling, commonly observed in tissues from aged organisms, has a negative effect on stem cell self-renewal and function (296 -299) . Interestingly, the PI3K/AKT and the mTOR pathways converge at several levels, which makes the so-called PI3K/ AKT/mTOR axis behave as a "molecular funnel" that integrates and canalizes many of the extracellular and intracellular inputs of the cell (300).
c. Effects on bone growth. Pharmacological loss-of-function studies have shown that in the GP, the mTOR pathway is mainly necessary for chondrocyte hypertrophic differentiation (288, 301) , although long-term rapamycin treatment in growing rats also revealed a role in chondrocyte proliferation, perhaps secondary to the impairment of IGF signaling (302) . Genetic loss of S6k1 in mice led to reduced growth, starting at embryonic stages and extending up to at least 11 weeks of age (303) .
The published gain-of-function experiments are more difficult to interpret. Chondrocyte-specific deletion of Lkb1, an inhibitor of mTOR activity, led to marked growth retardation by 3 weeks of age, associated with disorganized GP and very delayed hypertrophic differentiation, as revealed by dramatic expansion of immature chondrocytes and deficient mineralization (304) . On the other hand, conditional deletion of the PI3K negative regulator Pten in chondrocytes led to overactivation of the PI3K/AKT/mTOR pathway, associated with a mild overgrowth phenotype (305) . Unlike the Lkb1 mutants, there was no change in the height of the proliferative or hypertrophic zones; the whole process of endochondral ossification seemed accelerated, and GP fusion (which never happens in WT rodents) was observed at 6 months of age press.endocrine.org/journal/edrv (305) . The authors of this study hypothesized that loss of Pten accelerated exhaustion of GP progenitors, similar to what had been described for Pten deletion or for mTOR up-regulation in stem cell populations (296 -299, 306) , eventually triggering the aberrant GP fusion. The different outcomes obtained with these two approaches to increase PI3K/AKT/mTOR signaling in chondrocytes may indicate that the pathway plays different roles in different chondrocyte populations (proliferation and hypertrophy of nonresting chondrocytes, and regulation of stemness in resting chondrocytes), and that some components of the pathway are more important for one of these roles than for the other.
Hippo pathway
The Hippo pathway was discovered in Drosophila and has emerged as a major regulator of organ size and tumorigenesis through the control of cell number and differentiation (reviewed in Refs. [307] [308] [309] . It is composed of an extremely conserved kinase cascade, regulated by multiple upstream inputs and with multiple transcriptional outputs. Most of the effects of the pathway take place through the phosphorylation-dependent regulation of the subcellular location of the transcriptional coactivator Yesassociated protein (YAP) and its paralog transcriptional co-activator with PDZ-binding motif (TAZ). In general, activation of the kinase cascade (mammalian STE20-like protein kinase [MST] 1/2 first, and large tumor suppressor [LTS] 1/2 subsequently) results in YAP/TAZ phosphorylation, which leads on one hand to their sequestration in the cytoplasm and on the other to their degradation via E3 ubiquitin ligase. When the Hippo pathway is inactive, YAP/TAZ are not phosphorylated and can enter the nucleus where, in order to bind DNA and induce growth, they interact with transcription factors such as TEAD1-4 and others (see below). Here, we summarize the inputs that influence Hippo pathway activity, the different outcomes regulated by YAP/TAZ, including interactions with other signaling pathways, and the known effects of the Hippo/YAP axis on long bone growth.
a. Upstream regulators. The Hippo pathway is regulated by multiple extracellular and some intracellular inputs (reviewed in Refs. [307] [308] [309] . Some examples are cell polarity, GPCR signaling, mechanical cues, growth-factor-triggered RTK signaling (310) , and cellular stress (311) . Interestingly, it has been proposed that the actin cytoskeleton is the main mediator of many of the upstream regulators, although the mechanism is unclear. Microtubules have also been shown to regulate YAP/TAZ phosphorylation. Finally, cellular tension (through actomyosin) might also regulate YAP/TAZ activity.
b. Downstream outcomes and interaction with other signaling
pathways. The Hippo pathway controls multiple cellular behaviors, such as proliferation, differentiation, death, and growth (reviewed in Refs. [307] [308] [309] . This pleiotropy of functions is due to the variety of different binding partners that can interact with YAP/TAZ and because the transcriptional output of some of these complexes is cell-type dependent. Regarding the different transcriptional partners, it has been shown that TEADs are required for many YAP/TAZ activities, such as contact inhibition, epithelialto-mesenchymal transition, malignant transformation, apoptosis inhibition, and trophectoderm development. Other partners (p73, RUNX2, and FoxO1) mediate YAP/ TAZ effects on other processes (apoptosis, osteogenesis in mesenchymal stem cells, and cardiomyocyte survival during oxidative stress, respectively) (309, 312, 313) . Another reason for its pleiotropic effects is that the Hippo pathway interacts at several levels with other signaling pathways such as WNT, IGF, TGF␤/BMP, and NOTCH and has thus been proposed to be a signaling crossroads that integrates multiple inputs to control development and tissue homeostasis (reviewed in Refs. 307 and 309). Finally, as expected for two major regulators of organ size, the Hippo and mTOR pathways interact bidirectionally to coordinate cell growth and proliferation (314, 315) .
c. Effects on longitudinal growth. The few existing studies regarding the roles of the Hippo pathway on bone development and longitudinal growth are somewhat difficult to interpret. Genetic deletion of Mst1/2 in the whole mouse limb mesenchyme leads to the expected increase in chondrocyte proliferation and survival, but nonetheless the bones of the mutant animals are shorter than those of WT littermates, probably due to reduced chondrocyte size and increased cell density in the GP (316) . Given that RUNX2 regulates chondrocyte maturation (317, 318) and that YAP and RUNX2 can interact, it is possible that excessive YAP activity impairs chondrocyte differentiation by acting through RUNX2. Supporting this possibility, forced overexpression of RUNX2 in HTCs leads to delayed chondrocyte maturation and shorter long bones (319).
GPCR signaling and cross talk with RTK signaling
GPCRs respond to a variety of extracellular signals by directly activating/repressing signaling pathways related to proliferation, differentiation, and survival, and therefore have the potential to play a very important role in the extrinsic regulation of bone growth. In addition, we have already mentioned that GPCR-initiated signaling can interact with the Hippo and mTOR pathways at several levels, increasing the repertoire of signals that impinge on these two key growth regulatory pathways. One addi-tional characteristic is the reciprocal interaction of GPCRs with RTK pathways at the receptor and postreceptor levels. This interaction contributes to the observed growthpromoting activity of many GPCRs and to fine-tuning the outcome of the signal transduction of both pathways. We review the general evidence for the GPCR-RTK interaction and then provide some examples of the importance of GPCRs in bone growth.
a. GPCR-RTK interaction 1) Transactivation of RTKs by GPCRs (classical transactivation).
Several GPCR agonists are known to activate RTKs such as EGFR and FGFR. This phenomenon is called transactivation and may occur through ligand-dependent or -independent mechanisms (see Refs. 320 and 321). In the former, activation of GPCR signaling leads to the secretion of the RTK ligand. The ligand-independent cases are more frequent and are further subdivided into three categories: 1) the phosphorylation of the RTK by a Tyr kinase situated downstream of the GPCR; 2) the association of the GPCR with the RTK within protein complexes known as RTK-GPCR platforms, where the G␤␥-subunit modulates signaling downstream of the RTK (reviewed in Ref. 321); and 3) the production of reactive oxygen species downstream of GPCR signaling, which inhibit Tyr phosphatases, precluding the inhibition of RTK activity (320, 322) .
2) Activation of GPCR signaling by RTKs. Some ligand-bound RTKs require interaction with GPCR signaling molecules (eg, G proteins, ␤-arrestins) for efficient signal transduction (320, 321) . Alternatively, RTKs can transactivate the GPCRs themselves. The latter is called GPCR hijacking or GPCR jacking (320) , and it can involve either secretion of the cognate GPCR ligand upon activation of RTK signaling or the formation of RTK-GPCR partnerships, where the activity of some GPCR signaling components is modulated by the RTK.
The implications of these interactions are not only that GPCR and RTK signaling can modulate each other (explaining why the same ligand-receptor interaction can lead to different outcomes depending on the cell type), but also that ligand-independent activation of these receptors is possible, which is especially relevant in the case of GPCRs that are expressed far from the known sources of ligand (eg, ADRs in the GP).
b. Effects of GPCR signaling on chondrocytes and bone growth.
Chondrocytes express a good number of GPCRs, such as PTHR1, TSH receptor, melanocortin receptors, GPER, ADRs, neurokinin 1 receptor, NPR3, CXCR7, prostaglandin receptors, histamine H2 receptor, and probably others (reviewed in Ref. 323 ). Some of them are expressed throughout the GP, whereas others are spatially restricted, which coupled to their distinct affinities for different G proteins allows for a great variety of signaling possibilities. GPCRs have both direct and indirect effects on bone growth.
1) Indirect effects. Due to their cross talk with RTKs and other signaling pathways (see previous subsections), GPCRs can modulate/skew the outcome of said pathways in the GP. For instance, GPER/GPR30 plays an important role in bone growth (see Section III.B.2), most likely through modulation of IGF-1 serum levels (207) (208) (209) . It would be interesting to test to what extent ligand-independent GPCR-mediated modulation of IGF signaling and other RTK pathways takes place in the GP.
2) "Direct" effects. The role of the different G␣-subunits in chondrocyte biology was recently reviewed (323) and will be summarized here. Although we classify these effects as "direct," meaning that they have not been shown to be due to interactions of GPCRs with RTK, mTOR, or Hippo pathways, it is possible that this classification changes as more research is done in this field. The expression of G proteins is considered ubiquitous in the GP, although in particular cases it seems to be higher in prehypertrophic and HTCs (324) . Although the stimulatory G proteins have been shown to delay chondrocyte differentiation and G␣ s activity is required to maintain the resting chondrocytes in a quiescent state, G␣ q/11 activity promotes chondrocyte differentiation (324) . Moreover, in the absence of G␣ s signaling, G␣ q/11 activity is necessary for resting chondrocyte survival (324) . Although the main activator of G␣ s and G␣ q/11 in the GP seems to be PTHR1, an outstanding question remains-namely, whether the G␣ is also activated by other GPCRs-because some of the effects observed in the absence of G␣ take place in resting and proliferative chondrocytes, characterized by low or no Pthr1 expression (75) . Regarding the G␣ 12/13 family, although the downstream target of this family (RhoA) stimulates chondrocyte proliferation and inhibits hypertrophic differentiation in vitro, deletion of both members of this family in chondrocytes did not reveal any major defects in GP development (323, 324) . The predicted role of G␣ i in chondrocytes is the opposite to that of G␣ s , ie, to accelerate chondrocyte differentiation. This is interesting because HTCs express NPR3, which under certain circumstances can signal through G␣ i (325) , but the role of G␣ i in chondrocytes has not been tested so far.
In summary, it is becoming very apparent that the signals that regulate long bone growth and other organs do not operate alone or have a single fixed outcome. Instead, press.endocrine.org/journal/edrvwe propose that many potential growth regulatory inputs (extracellular, intracellular, organ-intrinsic, organ-extrinsic) are collected by at least one of the four interconnected signaling hubs we have reviewed (mTOR, Hippo, GPCRs, and RTKs). Then, by virtue of this network, the different signals are integrated, modulated, and funneled into a few coordinated outputs that impinge on the proximate regulators of cell growth, proliferation, and survival, such as cyclins and the ribosomal machinery ( Figure 6 ). We acknowledge that limiting the number of signaling hubs to four (and the number of receptor types to two) is based on our limited knowledge of the crosstalk within the GP system, and it could be a matter of opinion to a certain extent. In any event, a similar idea could be applied to a higher number of receptors/hubs. In addition, with respect to the signals that do not utilize RTKs or GPCRs (eg, BMPs, IHH, WNT), their receptors and/or their downstream signaling components have been shown to interact with components of the other pathways (eg, WNT, TGF␤, and NOTCH pathways interact with Hippo, whereas GLI activity is influenced by RTK and GPCR signaling), and therefore would still be processed by what we call filters at the receptor or postreceptor level (inner discs inside the funnel of Figure 6 ). An example of a postreceptor filter would be the negative influence that inflammation has on GH signaling. Very likely, different types of signals would probably need different numbers of processing steps, with some signals being fast-tracked. These fast-tracked signals would be the ones upon which other pathways converge (eg, IHH in chondrocytes) and that tend to have growth outcomes easy to predict. Importantly, most of the signals integrated along the way of this input/output converter would end up being translated into the regulation of the expression/activity of a few key transcription (co)factors (RUNX2, GLIs, YAP, SMADs, etc). In turn, these would exert two main possible actions: directly activate/inhibit some of the proximate growth regulators (eg, cyclinD1), or generate a secondary signal that would need to go through the converter again, either in the same cell (eg, many signals regulate the expression of IGF-1R) or a neighbor cell (eg, IHH secretion in response to mechanotransduction). Based on the known evidence, it appears that such a secondary signal would be more refined than the input and would therefore require less modulation when it went through the funnel in the receiving cell. With regard to human health, it is obvious that defects in any of the pathways described above have the potential to affect skeletal development, and in fact there are more than 370 genetic disorders affecting the human skeleton (326, 327) . Although a detailed description of all these disorders is beyond the scope of this review, Table 2 lists those affecting skeletal growth (327, 328) . Determining the rules of the signal-processing steps described above will be of vital importance to developing targeted therapies for these disorders. In the next section we review a growth regulatory process that we believe is an excellent model for gaining insight into critical molecular pathways.
IV. Catch-Up Growth
An effective approach to a problem as complex as the control of organ size is to perturb the system in a controlled manner and study if and how it recovers. As mentioned in Section II, in the case of canalization after growth reduction, the process is called catch-up growth (CUG). In this section we focus on long bones and review what is known about CUG, the possible underlying mechanisms, and the gaps in our knowledge.
A. Definition and types
CUG is defined as an increase in growth velocity after a temporary growth-delaying condition, as a means to return to the normal growth trajectory (see Figure 7A ) (reviewed in Refs. [3] [4] [5] . CUG involves a significant increase in growth rate; if a child or animal simply returns to the normal growth rate for their age, CUG is not considered to have occurred. In addition, at the beginning of the canalization phase, the bones are less mature than they should be (ie, the so-called bone age is lower than the animal's chronological age), but after CUG, skeletal maturity is back to normal. For the following discussions, it is also important to note that in parallel to the progressive maturation of growing bones over time, the rate of longitudinal growth decreases constantly after a speciesspecific postnatal age (Figure 7 , B-D), as part of the progressive growth deceleration exhibited by most organs in mammals (38, 330) .
Typical conditions that affect growth of the whole body and lead to CUG once resolved include impaired nutrition, celiac disease, GH deficiency, hypothyroidism, corticosteroid excess (eg, Cushing's syndrome), and intrauterine growth restriction (reviewed in Ref. 3) . Two basic types of CUG have been defined, depending on how canalization takes place ( Figure 7A ). In type A, the longitudinal growth rate can be several times the normal velocity for the bone age (331) , such that the normal growth trajectory is resumed very fast and growth rate goes back to normal from that point on. In type B, the animal still grows faster than it would according to the chronological age, but not faster than for its bone age. As a consequence, the animal keeps growing for a longer period than normal, and most of the catch-up takes place once control animals stop growing. Some authors have also proposed an AB type, character-ized by an initial growth rate that is faster than normal for bone age, which then transitions into a phase of normal growth rate for bone age, until the delayed puberty leads to further catch-up toward target height (4). The type, onset, and duration of the insult seem to influence the type of CUG. Type A CUG has been almost invariably observed after a period of malnutrition (reviewed in Ref. 3) , in Cushing syndrome patients after adrenal tumor removal (332) , and in timely treated cases of celiac disease, hypothyroidism, and GH deficiency (reviewed in Ref. 4) . If the treatment is not started early enough, however, most celiac, hypothyroidic, and GH-deficient patients recover after a type B CUG (4, 333, 334) . In addition, in human cases where two growth impairment periods and two subsequent CUG periods were described, the second CUG period was less effective, suggesting that there is a loss of recovery potential over time (331) . The impact that the timing of the insult and treatment seem to have on the type and outcome of CUG might reflect the importance of whether an injury occurs during allometric growth, such that type A CUG and full recovery can occur, or during isometric growth, which is more likely to lead to type B CUG and perhaps incomplete recovery (see Figure 2) .
B. Models of catch-up growth and mechanisms involved
Critical evaluation of the proposed models to explain CUG
Two main models have been proposed over the last 50 years to explain why a growth delay triggers CUG, the main difference between them being the distinction we made in Section II regarding the ability to compensate for cell loss. In many cases, the evidence for and against them is limited to mere correlations, underscoring the outstanding paucity of knowledge in this particular field. a. Neuroendocrine model (regulative, extrinsic). CUG was first described in cattle and humans as affecting the whole body (reviewed in Ref. 3) . The first theory to explain this phenomenon was that a neuroendocrine mechanism normally senses the size of the different tissues in the body, compares them with an internal time-dependent reference (possibly genetically encoded), and adjusts tissue size via hormonal release of a growth factor if a mismatch is found (332) . This so-called sizostat was proposed to detect tissue size by measuring secreted systemic factor(s) produced by each organ in proportion to their mass. Cells of the sizostat acted as a reference by hypothetically accumulating a receptor for the tissue-secreted substance in a time-dependent manner. It was further assumed that receptor levels were initially higher than ligand levels but then increased more slowly, and that the amount of growth factor released by the sizostat was proportional to the amount of free receptor. Such an extrinsic mechanism would explain the progressive reduction of growth rate and eventual growth cessation observed for all vertebrates (332) , in addition to the growth regulation observed in regulative organs. According to the model, in an organism experiencing a growth delay, the amount of free receptor would be greater than for normal animals, leading to higher growth rates and thus to CUG. The nervous system was considered the main candidate to perform the function of size mismatch assessment because it is the first system formed during development (332) , and its influence on peripheral tissues could be mediated by systemically released hormones (hence the name neuroendocrine). It was acknowledged from the beginning that this press.endocrine.org/journal/edrvmodel was an oversimplification based on many assumptions, but its main value was to provide testable hypotheses, a framework to build more elaborate theories as experimental results accumulated. Fifty years later, however, not much experimental evidence supporting this model has been provided. A notable exception is seen with mice heterozygous for a conditional deletion of Igf1r in the CNS. The mutation leads to a reduction in body growth (weight and length), starting at the third week of life and lasting into early adulthood (335) . Peripheral IGF-1R levels are not affected, and the growth defect correlates with diminished production of GH from the genetically WT pituitary gland due to reduced stimulation from the mutant hypothalamus. These results have been interpreted in light of the neuroendocrine hypothesis of growth control as meaning that IGF-1 is the substance produced by growing tissues and IGF-1R is the receptor expressed by cells of the sizostat (the hypothalamus in this case) (336) . In the CNS-specific Igf1r mutants, diminished hypothalamic IGF-1R expression would result in reduced levels of free IGF-1R. This would be "interpreted" as the animal being bigger than it actually is, resetting the GH-IGF axis such that hypothalamic stimulation of the pituitary gland (and therefore GH production and growth rate) are dampened earlier than normal (336) . Compatible with this interpretation is the fact that IGF-1R levels in the hypothalamus increase from the neonatal to adult periods in mice, as expected for the receptor expressed in the sizostat (337) . Despite this compatible evidence, other experimental results seem to be incompatible with the proposed systemic regulation of the neuroendocrine model (see below).
b. Proliferation-driven chondrocyte senescence (autonomous, intrinsic). It was shown 20 years ago that CUG can involve one organ only (338) , which was considered incompatible with the whole-body action of the model we just described. Indeed, partial CUG was observed in young rabbits after a transient growth delay induced by GC infusion exclusively in the proximal GP of the left tibia (338) . An autonomous model was proposed to explain this experiment, based on the idea that final bone size depends on the proliferative potential of chondrocytes. In this model, chondrocytes decrease their proliferation rate each time they divide until they become senescent. Accordingly, after a growth-delaying condition, GP chondrocytes would be developmentally younger than normal, and their unused proliferative potential would lead to CUG once the growth insult was resolved (338, 339) . This proliferative potential would be an intrinsic property of each GP, predetermining the final size of each bone. Importantly, the model assumes not only that the proliferative potential of chondrocytes is immutable, but also that GPs are closed systems, bearing a fixed number of progenitors. Resting chondrocytes were proposed to be the main candidates to carry the historical information of the GP (338) . This model is compatible with type B CUG, but it cannot a priori explain type A because in autonomous models growth rate cannot be higher than what corresponds to the developmental bone age. We will re-examine the current knowledge on the topic (mostly obtained by the Baron group) to better define the controversial aspects that require further investigation. There is indeed accumulating evidence supporting the progressive decline in both the function and cellularity of the GP with age (330, 340) . However, this decline does not seem to be a simple replicative senescence because it does not correlate with changes in telomere length (341) . GP senescence is probably part of the genetic program that was proposed to limit postnatal mammalian growth through involvement of a network of imprinted genes, introduced in Section II.C (36 -38) . For example, Igf2 is part of this network, and its expression was found to decrease almost 800-fold in the GP between young and old rats (120) . The molecular mechanisms underlying these expression changes, however, are not clear. Although some studies reported that GP senescence correlates with a general loss of DNA methylation in resting chondrocytes (342) , methylation of the promoter regions of the critical imprinted genes does not change with age (37) . Importantly, although the intrinsic model initially assumed that the senescent progression was cell-autonomous, we now know that primary resting chondrocytes undergo the same number of cell divisions in vitro regardless of the donor's age (17, 342) , suggesting that cell-nonautonomous mechanisms can regulate senescence. Indeed, differences in IGF-1R expression levels between different GPs correlate with differences in the amount of time these GPs can maintain a high proliferative index in the mouse (343) , suggesting that IGF signaling could be involved in the regulation of senescence (cell autonomous and nonautonomous). In addition, estrogens have been shown to accelerate senescence despite slowing down proliferation of resting chondrocytes (340).
Intrinsic and extrinsic mechanisms potentially involved in CUG
The evidence above raises the additional question of whether the regulation of chondrocyte senescence is exclusively GP intrinsic (ie, regulated by local signals) or can instead be regulated by signals from outside the GP. Grafting experiments in rabbits have shown that GPs grafted from 9-week-old donors to 17-week-old hosts (the reverse is technically unviable) keep growing at a rate according to the age of the donor during the following 5 weeks (344) . Of course, grafting experiments always present the caveat that the reconstituted structure may lack some of the intimate connectivity between cells that could be important to mediate extrinsic effects (such as the network of canaliculi that interconnects osteocytes, the mature cells embedded in bone) (345, 346) . Assuming that this is a minor problem, the grafting experiment a priori indicates that the proliferative potential of the GP is intrinsically regulated, but close examination of these results reveals two additional caveats. First, the GPs were not transplanted in isolation; rather, the whole knee was transplanted, including the surrounding muscle and connective tissue and a substantial portion of metaphyseal bone (344) . The grafting experiment therefore cannot rule out that the additional tissues have a GP-extrinsic effect on the proliferative potential of the GP. Second, the control experiments showed what could be considered a very interesting artifact: transplanted 9-week-old GPs always grew faster than the contralateral (unoperated) GPs, even when grafted to a 9-week-old host or when autologously grafted to the same animal (see Table 1 in Ref. 344 ). This transplantation-induced overgrowth was not observed in experiments using 17-week-old donors and hosts, and therefore the sole reason underlying the faster growth of 9-week-old knees grafted into 17-week-old hosts is that such tissue grows faster when transplanted, regardless of host age. Moreover, other experiments suggest that regulation of GP function is not exclusively intrinsic. For example, we have already mentioned that proximal and distal GP transposition within the same bone alters the growth rate of both GPs (281, 282) . Moreover, when the proximal GP of the tibia was surgically destroyed in young rabbits such that it could no longer contribute to tibial growth, overgrowth of the distal GP of the same bone was observed as compared to the contralateral limb (347) . Similarly, unilateral irradiation of the knee or wrist joints in dogs, while reducing overall growth of the irradiated bones, increased the amount of bone formed from the nonirradiated GPs of the same bones (348) . Our interpretation of these results is that growing long bones can be considered as organs with two morphogenetic units (the GPs), and if one of the morphogenetic units is eliminated, the remaining one can partially compensate by increasing its contribution to the organ's mass (similar to the example in Figure 3Bd ). Such a mechanism would involve growth-regulating feedback from the bone to the GP based on bone size. We speculate that there are two main possibilities for how this would work molecularly: 1) unequal sizes of left and right bones leads to unequal loading and therefore to unequal mechanical forces on the GPs of each bone, inducing different growth rates until a balanced weight load is reached; or 2) cells in the mature bone produce a diffusible factor in proportion to the bone's length/mass, and this factor has a negative effect on GP growth either directly, acting like a chalone, or indirectly, via a relay tissue (eg, the perichondrium/periosteum). Quantitative proteomic comparisons between focally injured and uninjured bones should shed light on the molecular nature of the mechanisms that can regulate individual GPs.
In summary, although GP-intrinsic mechanisms likely account for an important part of CUG, it remains to be determined to what extent extrinsic mechanisms contribute to the process, especially in cases such as type A CUG and overgrowth of a GP after an insult to its sister GP within the same bone. As explained in Section II.B, because the GP-intrinsic model of CUG assumes that the GP is autonomous, one very informative experiment would be to ablate some chondrocytes in a mosaic and transient fashion, instead of delaying their proliferation. According to the autonomous model, the remaining chondrocytes should continue to senesce normally, and therefore CUG would not be observed.
We now list the candidate signals potentially involved in CUG.
a. Systemic signals: crucial role of IGF signaling. To determine the mechanism(s) underlying whole-body CUG, the early studies tried to correlate the known growth characteristics of CUG with the effects of the known growth modulators. Adrenal androgens were soon discarded because they not only increase both height velocity and rate of skeletal maturity, but also have a virilizing effect not observed in CUG (331) . Years later, levels of the so-called sulfation factor (now known as somatomedin or IGF-1) were found increased in all cases of CUG, suggesting that CUG could not happen without increased IGF-1 (349, 350) . IGF-1 levels are invariably decreased upon food restriction (351, 352) and have been confirmed as a sensitive index for the degree of nutrition-induced CUG after intrauterine growth retardation in rats (353) . In normal children, longitudinal studies have revealed that IGF-1 levels in childhood positively correlate with subsequent leg and trunk growth and prepubertal height (354) . Moreover, in studies where 2-to 10-year-old children with intrauterine growth restriction were divided into CUG and non-CUG subgroups, the second group was found to have significantly lower IGF-1 levels (355) . In addition to this list of correlations, IGF signaling (in particular the MAPK/ERK branch) was recently found to be necessary for CUG after hypoxia in zebrafish (356) . There are some cases, however, in which increased IGF-1 levels do not correlate with CUG, such as hypothyroidism. As already discussed, T 3 and T 4 play direct and indirect roles in longitudinal growth, some of which are GH/IGF-independent, explaining why GH/ Besides IGF, correlations with other signals have been described. One study of CUG after malnutrition in children found that increased leptin concentration was only observed in children experiencing CUG (225) . Leptin concentration was much higher when malnutrition affected mainly the protein intake (225), suggesting some interaction with the mTOR pathway. In fact, leptin resistance in a model of CUG after intrauterine growth restriction in rats was associated with alterations in the AKT/mTOR pathway (357) .
Another factor with an extrinsic impact on CUG is renal function. Chronic renal failure leads to persistent growth retardation in approximately 36% of humans under the age of 21, with the growth rate being mainly reduced during the two human growth spurts (ie, 0 -3 y and puberty), but not midchildhood, which suggests that this condition mainly reduces the ability to accelerate growth velocity (see Ref. 358) . A study in prepubertal rats revealed that mild reduction of renal function through subtotal nephrectomy (barely affecting normal growth) impaired their ability for CUG after a 3-day food restriction (358) . Acceleration of growth rate took place much later in the refed nephrectomized animals than in controls and with lower intensity. The defective CUG was associated with a failure to increase chondrocyte proliferation and the size of the hypertrophic zone 1 week after refeeding (358) . However, 3 weeks after refeeding, the nephrectomized animals had caught-up with the controls, indicating that CUG was not abolished, only delayed (358) . GH supplementation reverted the delay in CUG in refed nephrectomized rats and had a much more profound effect on the size of the hypertrophic zone in these animals than in controls (358) . The molecular mechanisms leading to this greater sensitivity to GH in the GPs of nephrectomized rats are still unclear because other renal failure conditions lead to decreased GH sensitivity (359, 360) .
b. Local signals. Because CUG can happen after local GC infusion in the GP (338), there must be local molecular changes that drive CUG in the absence of a systemic response. There are two experimental approaches that have formally addressed this question: unilateral limb irradiation and unilateral bone fracture in growing animals. In the first case, although CUG did not happen, the initially arrested GP did resume normal growth rate for age (361) (362) (363) (364) . Despite a lack of CUG, transient local up-regulation of Igf2, Ccn2, Pthr1, and some cytokines and chemokines was observed (365) . In the second case, growing rats were subjected to tibial fracture in one limb, triggering up-regulation of Bmp6 and Bmpr1a in the proximal GP of the injured tibia by day 29 post trauma (366) . Because increased BMP signaling is predicted to have a positive effect on bone growth, these expression changes were hypothesized to be responsible for the overgrowth that had been previously associated with fractures in growing bones (366, 367) . The relevance of this experiment for CUG is that the equivalent GP of the contralateral unbroken tibia showed up-regulation of the same genes seen in the GP of the injured bone, possibly explaining why the unfractured limb did not lag behind the fractured one (366) . This hypothetical "cross talk" between limbs clearly deserves further exploration in the future.
So far, we have addressed whole-body CUG and singleorgan CUG as similar processes, but this assumption might be far from true. Indeed, there is no CUG after unilateral limb irradiation; and even the seminal experiment of the GP-intrinsic theory (transient unilateral GC infusion in rabbits) showed that a mild (ϳ4%) size reduction was not completely compensated after 20 weeks (338) . On the other hand, the same GC applied systemically led to an approximately 20% growth reduction that was fully compensated after only 16 weeks (212) . It is therefore conceivable that local and systemic CUG differ in their mechanisms because unilateral limb CUG requires that the injured bones grow faster than the rest of the organism (allometric growth), whereas during systemic CUG the whole body grows in concert (isometric). In fact, during whole-body CUG, the GPs respond with an early substantial increase in growth rate ( Figure 8A ) that correlates with an increase in the size of the hypertrophic zone (212) , whereas during recovery after a unilateral insult there is no such growth spurt ( Figure 8B ). Given the positive effect of IGF signaling on chondrocyte hypertrophy, it is possible that sustained activation of IGF signaling in the GP is permissive for complete CUG. Perhaps this condition can only be met by systemic elevation of IGF-1 levels, which as we discussed is generally associated with CUG. Importantly, a systemic response could still lead to local CUG if the injured GP(s) were sensitized to the systemic factor as a consequence of the growth delay. One possibility would be that differential mechanical loading due to the size defect regulates the expression levels of the receptor for the systemic factor. Another possibility would involve changes in the expression of receptors with age. For example, it has been shown that the levels of IGF-1R expression in the GP decrease with age (343) , and that many age-related expression changes are regulated by actual growth, not just the passing of time (38) . Therefore, we speculate that a local growth delay in the GP will result in the slowing down of the molecular aging process, leading for example to higher IGF-1R levels than in the unaffected GPs. Indeed, unilateral irradiation of the tibia leads to higher expression levels of members of the IGF signaling machinery in the irradiated GP as compared to the contralateral one (365) . The outstanding question here is whether the progressive molecular changes are exclusively GP-intrinsic or can be modulated by extrinsic factors. In any case, the ability to promote a local response to a systemically administered hormone would be very useful for the treatment of congenital limb asymmetries or GP injuries.
In summary, despite all the molecular advances in the last 30 years, perhaps the most accurate description of CUG is still the one proposed by Williams (6), which we paraphrase as follows: growth regulation is based on cells having a "growth program" and being able to recognize where they are in that program. Within each tissue, all the cells share the same program (eg, progressive senescence of chondrocytes) and are coordinated by tissue-intrinsic diffusible factors. Finally, coordination between different organs depends on their sharing the intrinsic growth programs (37, 38) and also on organextrinsic factors such as permissive hormones. We would like to add that the existence of extrinsic instructive factors able to reset organ-intrinsic programs cannot at this point be ruled out. Such a mechanism could explain ill-understood phenomena such as type A CUG or the compensatory overgrowth of the intact GP within an insulted bone when the injured GP cannot recover from the insult. Recruitment of new stem cells to the GP is another possibility worth exploring (368).
C. Long-term metabolic impact of catch-up growth
An aspect of CUG we have not discussed so far, very relevant from a clinical perspective (see next section), is that CUG may lead to undesired consequences. Growing evidence suggests that human infants and young animals that experience spontaneous or induced CUG have a significantly higher risk of developing adult-onset diseases such as mental retardation, metabolic syndrome, cardiovascular disease, and obesity (369 -371) . A common hypothesis to explain this association is that early growth restriction reprograms metabolism into a "thrifty" mode that persists later in life, leading to such problems in adulthood after normal conditions are restored. This thrifty metabolism is normally associated with the signaling pathways we have reviewed here, such as for example impaired PI3K activity in skeletal muscle, which results in self-sustained metabolic alterations (372) . This is obviously a field of very active research, and a recent study in rats suggested that there is a leptin-dependent "homeostatic set-point" program that acts in parallel to the thrifty metabolic program and is capable of overriding it (373) . Additional studies will be needed to deter- press.endocrine.org/journal/edrvmine whether this metabolic reversal is applicable to humans. The study of CUG is providing insights into some of the basic questions raised above that are at the core of developmental and regenerative biology. Once the mechanisms underlying CUG are discovered, harnessing them will provide a means to develop targeted noninvasive therapies for human growth disorders or localized tissue injuries. We are, however, far from that goal, and if we are to catch up (pun intended), more studies involving animal models of growth regulation will need to be developed. Ideally, growth modulation in these models should be inducible, to test the effect of the developmental age and magnitude of the size defect on growth regulation, and transient, such that recovery can be studied afterward. Some of the new models should affect the whole body, whereas others should be organ-specific to compare the extent and mechanisms of local vs systemic CUG. The models should also involve different types of insults, in particular delayed proliferation vs cell death, to gain an understanding of the cellular mechanisms driving recovery (or lack thereof) from each type of injury (see Section II.B). Along these lines, the proportion of cells affected is likely very relevant. For example, whereas the balanced replacement of unfit or damaged cells by fit ones (Section III.C) has not yet been described during limb growth, this might be due to experimental limitations. To unveil such mechanisms, a mixture of fit and unfit cell populations must be produced in the same limb, rather than most of the limb mesenchymal cells being altered. We suggest that mosaic approaches are needed, coupled with careful determination of the cellautonomous and cell-nonautonomous effects triggered by a particular growth defect.
V. Conclusions and Perspectives
Finally, although most of the studies (and this review) have focused in CUG after a growth delay, it is noteworthy that "lag down" or "catch-down" growth has been described within the first year of life for children born larger than normal for their gestational age (377) . It is of great interest to determine whether both types of canalization follow similar rules.
C. Coordination of paired organ growth as a powerful model to study growth regulation
Paired organs provide unique advantages to the study of growth regulation. As discussed before, by comparing the control organ of a pair from an experimental animal to the equivalent organ pair in an unmanipulated animal, it should be possible to discern whether local size recovery involves systemic mechanisms like those described in insects, where local damage to a developing tissue leads to delayed growth in the rest of the body (378, 379 ). An alternative result would be that systemic mechanisms are only triggered when both organs (or the whole body) are damaged. Finally, the approach of studying paired organs also provides the opportunity to detect compensatory mechanisms in the control organ of experimental animals.
D. The importance of the interplay between intrinsic and extrinsic growth regulators
The sheer complexity of growth regulation makes the design of therapies for growth disorders extremely difficult. Part of the problem is that signaling pathways interact extensively with each other, such that a particular signal can have variable effects depending on the cell context, the nutritional status of the patient, ongoing inflammatory processes, etc. For instance, brain-derived neurotrophic factor and CNP have been shown to tilt the balance between the p38 and ERK branches of MAPK signaling to-ward p38 in cultured chondrocytes (380) . Because the ERK pathway favors proliferation and the p38 branch favors chondrocyte differentiation, the enrichment of brain-derived neurotrophic factor and CNP receptor expression in HTCs would explain why IGF signaling promotes proliferation in proliferating chondrocytes while promoting differentiation in HTCs (380, 381) . Unfortunately, most studies have focused on the control of organ size by either organ-intrinsic or organ-extrinsic mechanisms, but few have attempted to decipher how these mechanisms interact to control organ scaling. We agree with Parker (382) in that such a holistic approach is the direction to go. Toward this goal, we propose that an important next step to elucidate the rules governing growth regulation will be to combine the traditional dissection of individual molecular pathways with genetic or pharmacological modulation of at least some of the four hubs we described (Hippo, mTOR, RTKs, and GPCRs). For example, comparison of the growth and metabolic effects of GH/IGF treatment alone and in combination with modulators of GPCR signaling should help us understand how the latter regulates the former, which could have very important clinical applications (see next section).
E. Relevance for pathophysiology
Growth disorders impact the quality of life at multiple levels. In addition to the obvious problems in locomotion, joint function, and esthetic self-perception, impaired growth also affects occupational and reproductive success in our society (383) (384) (385) . Therefore, there is widespread interest in the promotion of CUG in children born small for gestational age, via nutritional or hormonal supplementation. This approach might, however, bear undesired consequences, such as the metabolic disorders seen later in life. Although for GH supplementation there is no conclusive evidence regarding putative long-term detrimental effects, the problem of the potentially harmful metabolic effects associated with CUG is severe enough to raise questions about the most effective treatment for growth-impaired children. A deeper molecular understanding of the relationship between the desired effects of CUG (growth) and the side effects (metabolic disorders) should lead to therapies that uncouple both types of effects during spontaneous and stimulated CUG.
